Search results
New mechanism of immune evasion in squamous cell carcinoma offers potential for improved treatment
Medical Xpress· 2 hours agoA research group has revealed the tumor-extrinsic function of master regulator transcription...
Don’t Fry Day: Tips for Skin Cancer Awareness Month
KSDK St. Louis· 3 hours agoSiteman Cancer Center and the American Cancer Society share what to know about skincare during these hot summer months.
ASCO 2024: Merus touts positive Phase II data for head and neck cancer antibody
Pharmaceutical Technology via Yahoo Finance· 4 hours agoThe Phase II study is evaluating petosemtamab in combination with Merck & Co’s PD-1 inhibitor...
Adlai Nortye starts subject dosing in Phase II rectal cancer trial
Clinical Trials Arena via Yahoo Finance· 1 day agoIn November last year, the company concluded the subject enrolment in the Phase III BURAN trial of...
Rakuten Medical Announces Recent Interim Data from Phase 1b/2 Clinical Trial of ASP-1929...
FOX 5 San Diego· 4 hours agoThe data will be presented in a poster at the 2024 American Society of Clinical Oncology Annual Meeting (ASCO 2024) on June 2, 2024.
High-Stage cSCC: Outcomes Superior With Mohs vs WLE
Medscape· 2 days agoMohs surgery appears to be superior to wide local excision (WLE) in patients with high-stage cutaneous squamous cell carcinoma (cSCC) ...
Regeneron (REGN) Announces Positive Data on Oncology Candidate
Zacks via Yahoo Finance· 4 hours agoRegeneron's (REGN) REGN7075, in combination with its oncology drug Libtayo, generates anti-tumor...
The Current State Of Skin Cancer
Women s Health· 1 day agoThe American Academy of Dermatology also points out that the rates of melanoma in people under 50 are higher in women than in men. “The incidence of...
Mabwell Announces 9MW2821 Clinical Data and Latest Progress to be presented at 2024 ASCO Annual...
FOX 59 Indianapolis· 3 hours agoMabwell (688062.SH), an innovation-driven biopharmaceutical company, announced the data and latest...
ASCO: Early peek at Merus' bispecific cancer data lives up to investors' expectations
FierceBiotech· 4 hours agoAnalysts have hailed Merus’ latest data drop in head and neck cancer as meeting investors’...